Alnylam initiated with a Buy at Redburn Atlantic
Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Alnylam presents new data from HELIOS-B Phase 3 trial
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
The Business Journals12d
Alnylam wins FDA approval for rare heart disease drug
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...
STAT11d
Alnylam enters the ATTR-CM drug race
Also, Alnylam wins an important approval for ATTR-CM. The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to ...
Reuters12d
US FDA expands approval for Alnylam's drug to treat rare heart disease
Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM Pricing strategy crucial for Amvuttra's market share against oral options Alnylam is banking on the success of the drug ...
STAT12d
Alnylam drug wins FDA approval for progressive heart disease
The Food and Drug Administration cleared Alnylam Pharmaceuticals’ treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.